Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

v3.24.3
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Revenues, net $ 3,146 $ 8,365 $ 9,254 $ 40,885
Cost of revenues 3,311 6,038 10,328 21,590
Gross (loss) profit (165) 2,327 (1,074) 19,295
Operating expenses:        
Diagnostic expenses 0 132 0 1,932
General and administration 7,650 8,245 22,455 26,480
Research and development 122 428 533 1,144
Total operating expenses 7,772 8,805 22,988 29,556
Loss from operations (7,937) (6,478) (24,062) (10,261)
Interest income, net 0 1 0 39
Interest expense (1,158) (275) (2,316) (781)
Other (expense) income 0 (33) 12 (132)
Loss from operations before income taxes (9,095) (6,785) (26,366) (11,135)
Income tax benefit 2,508 1,644 7,361 3,104
Loss from operations after income taxes (6,587) (5,141) (19,005) (8,031)
Net loss (6,587) (5,141) (19,005) (8,031)
Other comprehensive income (loss):        
Unrealized gain (loss) on marketable securities 1 (2,032) 103 (2,201)
Total comprehensive loss $ (6,586) $ (7,173) $ (18,902) $ (10,232)
Loss per share:        
Basic (in dollars per share) $ (0.35) $ (0.30) $ (1.02) $ (0.47)
Diluted (in dollars per share) $ (0.35) $ (0.30) $ (1.02) $ (0.47)
Weighted average common shares outstanding:        
Weighted average common shares outstanding, basic (in shares) 19,079 17,175 18,672 16,924
Weighted average common shares outstanding, diluted (in shares) 19,079 17,175 18,672 16,924